I'm really confident that CRMD is going to hit between $25 and $50 by the end of the year. With their recent Q4 earnings showing substantial growth and securing 60% of outpatient centers, I see a lot of potential for this stock. It's got solid financials and a great product in Defencath, which makes it a strong play.

I believe CRMD is on the verge of significant growth due to its FDA-approved products and a strong foothold in the outpatient dialysis market. With forecasts for increasing revenues and profitability, I'm ready to hold onto this for the long haul, expecting it to really take off in 2025.